In this article, we review the methods of determining cell of origin (COO); use of COO in clinical practice; clinical trials in DLBCL according to COO; and future directions of tailoring treatment, including alternate categorization of genetic subtypes or clusters in DLBCL.
Antiretroviral therapy and rituximab show promise in aids-related diffuse large B-cell lymphoma patients.
A study shows pretreatment ctDNA levels and molecular responses are independently prognostic of outcomes in lymphomas.
Although the study found lurbinectedin isn't promising, the presence of a chromosomal 11q21-23 abnormality may open doors in treating the disease.
A study shows prescription drug coverage leads to better survival among Medicare beneficiaries with multiple myeloma.
Recent studies on CAR T-cell immunotherapy, and the recent approval of a new agent, add to evidence supporting the efficacy of these therapies.
A study shows bendamustine followed by venetoclax and obinutuzumab was active in treatment-naive or relapsed/refractory CLL.
Ibrutinib demonstrated superior response rates and survival in certain CLL patients despite exclusion from major clinical trials.
Using mediation analysis, researchers were able to identify three gene expression markers that help explain the observed prognostic difference between certain AML patients.
Investigations into the CSF3R gene may help lead to better classification and precise treatment of AML.